Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine?

<table>Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of recurrent new<i> falciparum</i> infection at day 28.</table>

Malaria Research and Treatment

fig5

Figure 5

Figure 5: Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine? 

Figure 5 | Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? 